Podcast

Investigating the Spreading Uptake of Sacubitril/Valsartan Across the US

In a study published in our December issue, researchers analyzed how prescribing of the newly approved heart failure drug sacubitril/valsartan diffused across the nation.

When new drugs are approved by the FDA, they can take time to diffuse across the population as clinicians begin to prescribe them. Uptake is not always quick or uniform, due to reasons that can include clinical inertia, provider familiarity, and the cost to patients.

On this episode of Managed Care Cast, we’re talking with the lead author of a study published in our December 2021 issue. The article, “Variation in Early Diffusion of Sacubitril/Valsartan and Implications for Understanding Novel Drug Diffusion,” describes how prescribing of the newly approved heart failure drug spread across the nation. Joining us today is Lauren Gilstrap, MD, MPH, of Dartmouth-Hitchcock Medical Center and The Dartmouth Institute for Health Policy and Clinical Practice.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Marilyn Glassberg, MD
Dr Caroline Vovan
1 expert is featured in this series.
1 expert is featured in this series.
Dr María Díez Campelo
Dr Caroline Vovan
Guy Young, MD
Dr Hans Lee
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo